Schnell to sell large shareholders’ stake

Published: 2012-07-24 06:57:00

Updated: 2012-07-24 06:57:00

Schnell Biopharmaceuticals said last Friday that it plans to sell the stake of large shareholders or dispose of stakes in its affiliated companies, without elaborating on the plan.

“We will make our regulatory filing about the selling within three months,” said a company official.

Schnell a...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK